Company: IOBT
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0000950170-25-058699
Chunk: 17

Company: IO Biotech, Inc.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 17
---
 for the compensation of the independent public accounting firm; • pre-approving audit and permitted non-audit and tax services to be provided to us by the independent public accounting firm; • reviewing our financial statements; • reviewing our critical accounting policies and estimates and internal controls over financial reporting; • establishing procedures for reviewing complaints received by us regarding accounting, internal accounting controls or auditing matters, including for the confidential anonymous submission of concerns by our employees, and periodically reviewing such procedures, as well as any significant complaints received, with management; • discussing with management and the independent registered public accounting firm the results of the annual audit and the reviews of our quarterly financial statements; • reviewing and approving any transaction between us and any related person in accordance with the Company’s related person transaction approval policy; and • attending to such other matters that may be specifically designated to the audit committee by our board of directors from time to time. All members of our audit committee meet the requirements for financial literacy under the applicable rules and regulations of the SEC and Nasdaq. Our board of directors has determined that Ms. Glaub and Mr. Smith are audit committee financial experts as defined under the applicable rules of the SEC and has the requisite financial sophistication as defined under the applicable rules and regulations of Nasdaq. Under the rules of the SEC and Nasdaq, members of the audit committee must also meet heightened independence standards. Our board of directors has determined that each member of the audit committee is independent under these heightened audit committee independence standards.

<div align='center'>12</div>

Compensation Committee

Our board of directors has established a compensation committee and adopted a compensation committee charter. Specific responsibilities of our compensation committee include:

reviewing and recommending policies related to compensation and benefits received by our officers and employees, including reviewing and approving corporate goals and objectives relevant to compensation of the Chief Executive Officer and other senior officers;

evaluating the performance of the Chief Executive Officer and other senior officers in light of those goals and objectives;

setting compensation of the Chief Executive Officer and other senior officers based on such evaluations;

administering the issuance of options and other awards under our equity-based incentive plans;

reviewing and approving, for the Chief Executive Officer and other senior officers, employment agreements, severance agreements, consulting agreements and change in control or termination agreements; and

attending to such other matters that may be specifically designated to the compensation committee by our board of directors from time to time.

Each of the members of our compensation committee has been determined to be independent under the applicable rules and regulations of Nasdaq, after